NATIONAL QUALITY FORUM

Measure Submission and Evaluation Worksheet 5.0

This form contains the information submitted by measure developers/stewards, organized according to NQF's measure evaluation criteria and process. The evaluation criteria, evaluation guidance documents, and a blank online submission form are available on the submitting standards web page.

NQF #: 0386   **NQF Project:** Cancer Project
(for Endorsement Maintenance Review) **Original Endorsement Date:** Jul 31, 2008 **Most Recent Endorsement Date:** Jul 31, 2008

BRIEF MEASURE INFORMATION
De.1 Measure Title: Oncology: Cancer Stage Documented
Co.1.1 Measure Steward: American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)
De.2 Brief Description of Measure: Percentage of patients, regardless of age, with a diagnosis of breast, colon, or rectal cancer who are seen in the ambulatory setting who have a baseline AJCC cancer stage or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period
2a1.1 Numerator Statement: Patients who have a baseline AJCC cancer stage* or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period Numerator Instructions: *Cancer stage refers to stage at diagnosis
2a1.4 Denominator Statement: All patients, regardless of age, with a diagnosis of breast, colon, or rectal cancer who are seen in the ambulatory setting
2a1.8 Denominator Exclusions: None
1.1 Measure Type: Process **2a1. 25-26 Data Source:** Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Pharmacy, Paper Records **2a1.33 Level of Analysis:** Clinician : Group/Practice, Clinician : Individual, Clinician : Team **1.2-1.4 Is this measure paired with another measure?** No **De.3 If included in a composite, please identify the composite measure** (*title and NQF number if endorsed*):

STAFF NOTES (*issues or questions regarding any criteria*)
Comments on Conditions for Consideration:
Is the measure untested? Yes☐ No☐   If untested, explain how it meets criteria for consideration for time-limited endorsement:
1a. Specific national health goal/priority identified by DHHS or NPP addressed by the measure (*check De.5*): 5. Similar/related endorsed or submitted measures (*check 5.1*): Other Criteria:
Staff Reviewer Name(s):

1. IMPACT, OPPORTUNITY, EVIDENCE - IMPORTANCE TO MEASURE AND REPORT
Importance to Measure and Report is a threshold criterion that must be met in order to recommend a measure for endorsement. All

three subcriteria must be met to pass this criterion. See guidance on evidence.
Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria. (evaluation criteria)

1a. High Impact: H☐ M☐ L☐ I☐
(*The measure directly addresses a specific national health goal/priority identified by DHHS or NPP, or some other high impact aspect of healthcare.*)

De.4 Subject/Topic Areas (*Check all the areas that apply*): Cancer, Cancer : Breast, Cancer : Colorectal
De.5 Cross Cutting Areas (*Check all the areas that apply*):

1a.1 Demonstrated High Impact Aspect of Healthcare: Affects large numbers, A leading cause of morbidity/mortality, Patient/societal consequences of poor quality, Severity of illness

1a.2 If "Other," please describe:

1a.3 Summary of Evidence of High Impact (*Provide epidemiologic or resource use data*):
Breast cancer
An estimated 230,480 new cases of invasive breast cancer are expected to occur among women in the US during 2011; about 2,140 new cases are expected in men. Excluding cancers of the skin, breast cancer is the most frequently diagnosed cancer in women.(1) On January 1, 2008, in the United States there were approximately 2,632,005 women alive who had a history of cancer of the breast, [including both persons with active disease and those who are cured of their disease.](2) An estimated 39,970 breast cancer deaths (39,520 women, 450 men) are expected in 2011. Breast cancer ranks second as a cause of cancer death in women (after lung cancer).(1) The 5 year relative survival rate for female breast cancer patients has improved from 63% in the early 1960s to 90% today.(1) Based on rates from 2006-2008, 12.29% of women born today will be diagnosed with cancer of the breast at some time during their lifetime.(2)

Colorectal Cancer
An estimated 101,340 cases of colon and 39,870 cases of rectal cancer are expected to occur in 2011. Colorectal cancer is the third most common cancer in both men and women.(1) On January 1, 2008, in the United States there were approximately 1,110,077 men and women alive who had a history of cancer of the colon and rectum -- 542,127 men and 567,950 women, [including both persons with active disease and those who are cured of their disease.](2) An estimated 49,380 deaths from colorectal cancer are expected to occur in 2011, accounting for about 9% of all cancer deaths. (1) The 1 and 5 year relative survival rates for persons with colorectal cancer are 83% and 65%, respectively. Survival continues to decline beyond 5 years to 58% at 10 years after diagnosis. (1) Based on rates from 2006-2008, 5.08% of men and women born today will be diagnosed with cancer of the colon and rectum at some time during their lifetime.(2)

1a.4 Citations for Evidence of High Impact cited in 1a.3: Quoted verbatim from the following sources:

(1) American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society; 2011.
(2) Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.

1b. Opportunity for Improvement: H☐ M☐ L☐ I☐
(*There is a demonstrated performance gap - variability or overall less than optimal performance*)

1b.1 Briefly explain the benefits (improvements in quality) envisioned by use of this measure:
Cancer stage is a critical component in determining treatment options for patients with cancer. Despite its importance, cancer stage is often not documented in the medical record.

1b.2 Summary of Data Demonstrating Performance Gap (*Variation or overall less than optimal performance across providers*):
[*For Maintenance – Descriptive statistics for performance results for this measure - distribution of scores for measured entities by quartile/decile, mean, median, SD, min, max, etc.*]
ASCO´s Quality Oncology Practice Initiative (QOPI®) includes a slight adaptation of this measure assessing the documentation of

stage within one month of the first office visit. Among 388 self-selected participating practices, an average performance rate of 83.98% was found for this measure with variation among practices ranging from 35.92% to 100% (N charts=23876). QOPI is a physician-led, voluntary, practice-based, quality-improvement program using performance measurement and benchmarking among oncology practices across the United States. (1)

Among physicians participating in ASTRO's Performance Assessment for the Advancement of Radiation Oncology Treatment (PAAROT) program, an average performance rate of 87% was reported for this measure with variation among physicians ranging from 10-100%. PAAROT is a practice improvement program that enables a physician to analyze their practice and evaluate their strengths and areas for improvement.(2)

A recent analysis of the quality of colorectal cancer care provided by academic and community sites in the United States found that only 38% of the 499 eligible medical records reported TNM stage and 73% documented stage by any clinical notation.(3)

1b.3 Citations for Data on Performance Gap: [*For Maintenance – Description of the data or sample for measure results reported in 1b.2 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included*]
(1) American Society of Clinical Oncology. Quality Oncology Practice Initiative. Unpublished data, fall 2011.
(2) American Society for Radiation Oncology. Performance Assessment for the Advancement of Radiation Oncology Treatment program (PAAROT). Unpublished data, 2010.
(3) Abernethy AP, Herndon JE II, Wheeler JL, et al: Poor documentation prevents adequate assessment of quality metrics in colorectal cancer. J Oncol Pract 5:167-174, 2009.

1b.4 Summary of Data on Disparities by Population Group: [*For Maintenance –Descriptive statistics for performance results for this measure by population group*]
We are not aware of any publications/evidence outlining disparities in documentation of cancer staging however the National Cancer Institute and AHRQ´s National Healthcare Disparities Report has shown that disparities exist in cancer incidence and deaths by race, ethnicity and socioeconomic status. (1,2)

1b.5 Citations for Data on Disparities Cited in 1b.4: [*For Maintenance – Description of the data or sample for measure results reported in 1b.4 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included*]
(1) Harper S, Lynch J. Methods for Measuring Cancer Disparities: Using Data Relevant to Healthy People 2010 Cancer-Related Objectives. Cancer Control Monograph Series, No. 6. Bethesda, MD: National Cancer Institute; 2005. NIH publication 05-5777.
(2)Agency for Healthcare Research and Quality. 2010 National Healthcare Disparities Report. http://www.ahrq.gov/qual/nhdr10/nhdr10.pdf. Published March 2011. Accessed January 3, 2011.

1c. Evidence (*Measure focus is a health outcome OR meets the criteria for quantity, quality, consistency of the body of evidence.*)
Is the measure focus a health outcome?   Yes☐ No☐   If not a health outcome, rate the body of evidence.

Quantity: H☐ M☐ L☐ I☐   Quality: H☐ M☐ L☐ I☐   Consistency: H☐ M☐ L☐ I☐

Quantity	Quality	Consistency	Does the measure pass subcriterion1c?
M-H	M-H	M-H	Yes☐
L	M-H	M	Yes☐ IF additional research unlikely to change conclusion that benefits to patients outweigh harms: otherwise No☐
M-H	L	M-H	Yes☐ IF potential benefits to patients clearly outweigh potential harms: otherwise No☐
L-M-H	L-M-H	L	No ☐

Health outcome – rationale supports relationship to at least one healthcare structure, process, intervention, or service	Does the measure pass subcriterion1c? Yes☐ IF rationale supports relationship

1c.1 Structure-Process-Outcome Relationship *(Briefly state the measure focus, e.g., health outcome, intermediate clinical outcome, process, structure; then identify the appropriate links, e.g., structure-process-health outcome; process- health outcome; intermediate clinical outcome-health outcome)*:
The measure focus is on the documentation of cancer stage in breast and colorectal cancer patients. Cancer stage is key to the

implementation of therapeutic interventions demonstrated to improve survival and decrease the risk of recurrence.

1c.2-3 Type of Evidence *(Check all that apply)*:
Clinical Practice Guideline

1c.4 Directness of Evidence to the Specified Measure *(State the central topic, population, and outcomes addressed in the body of evidence and identify any differences from the measure focus and measure target population)*:
Clinical practice guidelines for breast and colorectal cancer recommend staging to allow for efficient identification of local treatment options, assists in identifying systemic treatment options, allows the comparison of outcome results across institutions and clinical trials, and provides baseline prognostic information.

The measure focus is on the documentation of cancer stage in breast and colorectal cancer patients.

1c.5 Quantity of Studies in the Body of Evidence *(Total number of studies, not articles)*: The description of the evidence review in the guideline did not address the overall quantity of studies in the body of evidence. However, 457 articles are cited in NCCN´s breast cancer guideline´s reference section. 387 and 271 articles are cited in NCCN´s colon and rectal cancer guidelines.

1c.6 Quality of Body of Evidence (*Summarize the certainty or confidence in the estimates of benefits and harms to patients across studies in the body of evidence resulting from study factors. Please address: a) study design/flaws; b) directness/indirectness of the evidence to this measure (e.g., interventions, comparisons, outcomes assessed, population included in the evidence); and c) imprecision/wide confidence intervals due to few patients or events*): The quality of the body of evidence supporting the guideline recommendation is summarized according to the NCCN categories of evidence and consensus as being based on "lower-level evidence". Lower-level evidence is later described as evidence that may include non-randomized trials; case series; or when other data are lacking, the clinical experience of expert physicians.

1c.7 Consistency of Results across Studies *(Summarize the consistency of the magnitude and direction of the effect)*: Although there is no explicit statement regarding the overall consistency of results across studies in the guidelines supporting the measure, the recommendation received uniform NCCN consensus that the intervention is appropriate.

1c.8 Net Benefit *(Provide estimates of effect for benefit/outcome; identify harms addressed and estimates of effect; and net benefit - benefit over harms)*:
Cancer stage is key to the implementation of therapeutic interventions demonstrated to improve survival and decrease the risk of recurrence. The documentation of cancer stage is therefore critical as it provides a means by which this information can readily be communicated to others, to assist in therapeutic decisions, and to help estimate prognosis.

1c.9 Grading of Strength/Quality of the Body of Evidence. Has the body of evidence been graded? Yes

1c.10 If body of evidence graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias: A panel of experts with members from each of the NCCN Member Institutions develops the NCCN Guidelines. Specialties that must be included on a particular panel are identified before that panel is convened but also evolve as the standard of care changes over time. This multidisciplinary representation varies from panel to panel. The NCCN Guidelines Panel Chairs are charged with ensuring that representatives of all treatment strategies are included. Many of the panels also include a patient representative, especially when issues of long-term care and patient preference are paramount in the panel´s considerations.

NCCN publishes individual disclosures of potential conflicts of interest for panel members, NCCN Guidelines staff, and NCCN senior management. Relationships disclosed include research funding, participation in advisory groups, participation in speakers' bureaus, employment, and equity or patent ownership. Beginning in 2010, the NCCN Board of Directors has directed that panel members compensation from external sources be less than published thresholds. These thresholds are <= $20,000 from a single entity and <= $50,000 in aggregate from any source.

1c.11 System Used for Grading the Body of Evidence: Other

1c.12 If other, identify and describe the grading scale with definitions: NCCN Categories of Evidence and Consensus Panel members identify the level of evidence supporting each recommendation. These categories are:

•Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
•Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
•Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
•Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

1c.13 Grade Assigned to the Body of Evidence: Category 2A

1c.14 Summary of Controversy/Contradictory Evidence: No controversy or contradictory evidence reported.

1c.15 Citations for Evidence other than Guidelines*(Guidelines addressed below)*:

1c.16 Quote verbatim, <u>the specific guideline recommendation</u> *(Including guideline # and/or page #)*:
Breast Cancer
All patients with breast cancer should be assigned a clinical stage of disease, and if appropriate evaluation is available, a pathologic stage of disease. The routine use of staging allows for efficient identification of local treatment options, assists in identifying systemic treatment options, allows the comparison of outcome results across institutions and clinical trials, and provides baseline prognostic information….A central component of the treatment of breast cancer is full knowledge of extent of disease and biologic features. These factors contribute to the determination of the stage of disease, assist in the estimation of the risk that cancer will recur, and provide information that predicts response to therapy (e.g., hormone receptors and human epidermal growth factor receptor 2 [HER2]). (1)

Colon Cancer
Some of the criteria that should be included in the report of the pathologic evaluation include the following: grade of the cancer; depth of penetration and extension to adjacent structures (T); number of regional lymph nodes evaluated; number of positive regional lymph nodes (N); an assessment of the presence of distant metastases to other organs, the peritoneum of an abdominal structure, or in non-regional lymph nodes (M); the status of proximal, distal, and radial margins; lymphovascular invasion; perineural invasion; and extra-nodal tumor deposits. (2)

Rectal Cancer
Some of the information that should be detailed in the report of the pathologic evaluation of rectal cancer includes: (1) gross description of the tumor and specimen; (2) grade of the cancer; (3) depth of penetration and extension to adjacent structures (T); (4) number of regional lymph nodes evaluated; (5) number of positive regional lymph nodes (N); (6) the presence of distant metastases to other organs or sites including non-regional lymph nodes (M); (7) the status of proximal, distal, and circumferential (radial) margins; (8) neoadjuvant treatment effect; (9) lymphovascular invasion; (10) perineural invasion; and (11) the number of tumor deposits. (3)

1c.17 Clinical Practice Guideline Citation: (1) National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2, 2011. Available at: http://www.nccn.org.
(2) National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2, 2012. Available at: http://www.nccn.org.
(3) National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 2, 2012. Available at: http://www.nccn.org.

1c.18 National Guideline Clearinghouse or other URL: www.nccn.org

1c.19 Grading of Strength of Guideline Recommendation. Has the recommendation been graded? Yes

1c.20 If guideline recommendation graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias: Same as in 1.c.10 above.

1c.21 **System Used for Grading the Strength of Guideline Recommendation:** Other

1c.22 **If other, identify and describe the grading scale with definitions:** NCCN Categories of Evidence and Consensus Panel members identify the level of evidence supporting each recommendation. These categories are:

•Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
•Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
•Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
•Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

1c.23 **Grade Assigned to the Recommendation:** Category 2A

1c.24 **Rationale for Using this Guideline Over Others:** It is the PCPI policy to use guidelines, which are evidence-based, applicable to physicians and other health-care providers, and developed by a national specialty organization or government agency. In addition, the PCPI has now expanded what is acceptable as the evidence base for measures to include documented quality improvement (QI) initiatives or implementation projects that have demonstrated improvement in quality of care.

Based on the NQF descriptions for rating the evidence, what was the <u>developer's assessment</u> of the quantity, quality, and consistency of the body of evidence? **1c.25** Quantity: Moderate **1c.26** Quality: Moderate **1c.27** Consistency: Moderate
Was the threshold criterion, *Importance to Measure and Report*, met? (*1a & 1b must be rated moderate or high and 1c yes*) Yes☐ No☐ Provide rationale based on specific subcriteria:
For a new measure if the Committee votes NO, then STOP. For a measure undergoing endorsement maintenance, if the Committee votes NO because of 1b. (no opportunity for improvement), it may be considered for continued endorsement and all criteria need to be evaluated.

2. RELIABILITY & VALIDITY - SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES
Extent to which the measure, <u>as specified</u>, produces consistent (reliable) and credible (valid) results about the quality of care when implemented. (<u>evaluation criteria</u>) Measure testing must demonstrate adequate reliability and validity in order to be recommended for endorsement. Testing may be conducted for data elements and/or the computed measure score. Testing information and results should be entered in the appropriate field. Supplemental materials may be referenced or attached in item 2.1. See <u>guidance on measure testing</u>.
S.1 **Measure Web Page** *(In the future, NQF will require measure stewards to provide a URL link to a web page where current detailed specifications can be obtained)*. Do you have a web page where current detailed specifications for <u>this</u> measure can be obtained? Yes **S.2** **If yes, provide web page URL:** www.physicianconsortium.org
2a. RELIABILITY. Precise Specifications and Reliability Testing: H☐ M☐ L☐ I☐
2a1. Precise Measure Specifications. (*The measure specifications precise and unambiguous.*)
2a1.1 **Numerator Statement** *(Brief, narrative description of the measure focus or what is being measured about the target population, e.g., cases from the target population with the target process, condition, event, or outcome)*: Patients who have a baseline AJCC cancer stage* or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period Numerator Instructions: *Cancer stage refers to stage at diagnosis **2a1.2** **Numerator Time Window** *(The time period in which the target process, condition, event, or outcome is eligible for inclusion)*:

At least once during the measurement period

2a1.3 Numerator Details *(All information required to identify and calculate the cases from the target population with the target process, condition, event, or outcome such as definitions, codes with descriptors, and/or specific data collection items/responses)*:
For EHR:
eSpecification currently under development. Data elements (using the Quality Data Model) required for the measure attached.

For Claims/Administrative Data:
To submit the numerator option for patients who have a baseline AJCC cancer stage or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period, report one of the following CPT Category II codes:

3300F – American Joint Committee on Cancer (AJCC) stage documented and reviewed
OR
3301F – Cancer stage documented in medical record as metastatic and reviewed

2a1.4 Denominator Statement *(Brief, narrative description of the target population being measured)*:
All patients, regardless of age, with a diagnosis of breast, colon, or rectal cancer who are seen in the ambulatory setting

2a1.5 Target Population Category *(Check all the populations for which the measure is specified and tested if any)*: Adult/Elderly Care

2a1.6 Denominator Time Window *(The time period in which cases are eligible for inclusion)*:
12 consecutive months

2a1.7 Denominator Details (*All information required to identify and calculate the target population/denominator such as definitions, codes with descriptors, and/or specific data collection items/responses)*:
For EHR:
eSpecification currently under development. Data elements (using the Quality Data Model) required for the measure attached.

For Claims/Administrative Data:
All patients, regardless of age, with a diagnosis of breast, colon, or rectal cancer who are seen in the ambulatory setting
AND
ICD-9-CM diagnosis codes: 153.0, 153.1, 153.2, 153.3, 153.4, 153.5, 153.6, 153.7, 153.8, 153.9 (malignant neoplasm of colon), 154.0, 154.1, 154.2, 154.3, 154.8 (malignant neoplasm of rectum and anus), 174.0, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9 (malignant neoplasm of female breast), V10.3, V10.05, V10.06
ICD-10-CM diagnosis codes: C18.3, C18.4, C18.6, C18.7, C18.0, C18.1, C18.2, C18.5, C18.8, C18.9, C19, C20, C21.1, C21.0, C21.2, C21.8, C50.011, C50.012, C50.019, C50.111, C50.112, C50.119, C50.211, C50.212, C50.219, C50.311, C50.312, C50.319, C50.411, C50.412, C50.419, C50.511, C50.512, C50.519, C50.611, C50.612, C50.619, C50.811, C50.812, C50.819, C50.911, C50.912, C50.919, Z85.3, Z85.038, Z85.048
AND either option 1 or 2

1. Chemotherapy
•   CPT codes:
o   99201, 99202, 99203, 99204, 99205,
o   99212, 99213, 99214, 99215,
o   99241, 99242, 99243, 99244, 99245,
o   99024

OR

2. Radiation therapy
•   CPT codes for radiation treatment planning: 77261, 77262, 77263

2a1.8 Denominator Exclusions *(Brief narrative description of exclusions from the target population)*:

None

2a1.9 Denominator Exclusion Details *(All information required to identify and calculate exclusions from the denominator such as definitions, codes with descriptors, and/or specific data collection items/responses)*:
There are no exceptions for this measure.

2a1.10 Stratification Details/Variables *(All information required to stratify the measure results including the stratification variables, codes with descriptors, definitions, and/or specific data collection items/responses)*:
We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

2a1.11 Risk Adjustment Type *(Select type. Provide specifications for risk stratification in 2a1.10 and for statistical model in 2a1.13)*: No risk adjustment or risk stratification **2a1.12 If "Other," please describe:**

2a1.13 Statistical Risk Model and Variables *(Name the statistical method - e.g., logistic regression and list all the risk factor variables. Note - risk model development should be addressed in 2b4.)*:
None

2a1.14-16 Detailed Risk Model Available at Web page URL (or attachment). Include coefficients, equations, codes with descriptors, definitions, and/or specific data collection items/responses. Attach documents only if they are not available on a webpage and keep attached file to 5 MB or less. NQF strongly prefers you make documents available at a Web page URL. Please supply login/password if needed:

2a1.17-18. Type of Score: Rate/proportion

2a1.19 Interpretation of Score *(Classifies interpretation of score according to whether better quality is associated with a higher score, a lower score, a score falling within a defined interval, or a passing score)*: Better quality = Higher score

2a1.20 Calculation Algorithm/Measure Logic *(Describe the calculation of the measure score as an ordered sequence of steps including identifying the target population; exclusions; cases meeting the target process, condition, event, or outcome; aggregating data; risk adjustment; etc.)*:
To calculate performance rates:
1) Find the patients who meet the initial patient population (ie, the general group of patients that the performance measure is designed to address).
2) From the patients within the initial patient population criteria, find the patients who qualify for the denominator (ie, the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial patient population and denominator are identical.
3) From the patients within the denominator, find the patients who qualify for the Numerator (ie, the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator
4) If the measure does not have exceptions, STOP. If the measure does have exceptions, proceed with the following steps. From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception, when exceptions have been specified. If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI.

If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure.

See calculation algorithm in attachment 2a1.21.

2a1.21-23 Calculation Algorithm/Measure Logic Diagram URL or attachment:
Attachment
AMA-PCPI_Measure Calculation-Standard Measures-634620735019045822.pdf

2a1.24 Sampling (Survey) Methodology. If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate):
Not applicable. The measure does not require sampling or a survey.

2a1.25 Data Source (*Check all the sources for which the measure is specified and tested*). If other, please describe:
Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Pharmacy, Paper Records

2a1.26 Data Source/Data Collection Instrument (*Identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.*): Not Applicable

2a1.27-29 Data Source/data Collection Instrument Reference Web Page URL or Attachment:

2a1.30-32 Data Dictionary/Code Table Web Page URL or Attachment:
Attachment
Data_Elements_0386.xls

2a1.33 Level of Analysis (*Check the levels of analysis for which the measure is specified and tested*): Clinician : Group/Practice, Clinician : Individual, Clinician : Team

2a1.34-35 Care Setting (*Check all the settings for which the measure is specified and tested*): Ambulatory Care : Clinician Office, Other:Oncology/Outpatient Clinic;

2a2. Reliability Testing. (*Reliability testing was conducted with appropriate method, scope, and adequate demonstration of reliability.*)

2a2.1 Data/Sample (*Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included*):
PCPI Testing Project
Five practice sites representing various types, locations and sizes were identified to participate in testing the PCPI/ASCO/ASTRO-developed measures.
o   Site A: hospital, multi-practice sites in urban, rural and suburban settings; 21 physicians; average 9600 oncology/prostate cancer patient visits per month for MD/NP assessment, chemotherapy; submitted PQRS claims for one measure and utilized a full-fledged EHR.
o   Site B: physician owned private practice, suburban setting; 4 physicians; average 48 oncology/prostate cancer patients seen per day; submitted PQRS claims for one measure and utilized paper medical records.
o   Site C: physician owned private practice, urban setting; 41 physicians; average 2500 oncology/prostate cancer patients seen per month; submitted PQRS claims for two measures and utilized a full-fledged EHR.
o   Site D: academic, suburban setting; 9 physicians; average 240 oncology/prostate cancer patients seen per month; submitted PQRS claims for one measure and utilized paper and EHR.
o   Site E: academic, urban setting; 14 physicians; average 250 oncology/prostate cancer patients seen per month; collected PQRS data on 3 measures and utilized a full-fledged EHR.
•   The measurement period (data collected from patients seen) was 1/1/2010 through 12/31/2010.
•   Chart abstraction was performed between 8/8/2011 and 11/3/2011.

2a2.2 Analytic Method (*Describe method of reliability testing & rationale*):
PCPI Testing Project
Data abstracted from patient records were used to calculate inter-rater reliability for the measure.

160 patient records were reviewed.

Data analysis included:
- Percent agreement; and
- Kappa statistic to adjust for chance agreement.

2a2.3 Testing Results *(Reliability statistics, assessment of adequacy in the context of norms for the test conducted)*:
PCPI Testing Project
N, % Agreement, Kappa (95% Confidence Interval)
Overall Reliability: 160, 100.0%, Kappa is noncalculable*
Denominator Reliability: 160, 100.0%, Kappa is noncalculable*
Numerator Reliability: 160, 100.0%, Kappa is noncalculable*

This measure demonstrates perfect reliability, as shown in results from the above analysis.

*Kappa Statistics cannot be calculated because of complete agreement. Confidence intervals cannot be calculated because to do so would involve dividing by zero which cannot be done.

2b. VALIDITY. Validity, Testing, <u>including all Threats to Validity</u>:   H☐ M☐ L☐ I☐

2b1.1 Describe how the measure specifications *(measure focus, target population, and exclusions)* **are consistent with the evidence cited in support of the measure focus** *(criterion 1c)* **and identify any differences from the evidence:**
Clinical practice guidelines for breast and colorectal cancer recommend staging to allow for efficient identification of local treatment options, assists in identifying systemic treatment options, allows the comparison of outcome results across institutions and clinical trials, and provides baseline prognostic information.

The measure focus is on the documentation of cancer stage in breast and colorectal cancer patients.

2b2. Validity Testing. (*Validity testing was conducted with appropriate method, scope, and adequate demonstration of validity.*)

2b2.1 Data/Sample *(Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included)*:
An expert panel was used to assess face validity of the measure. This panel consisted of the following 31 members, with representation from a number of specialties including oncology, radiation oncology, surgical oncology, urology, gastroenterology, hematology, pathology, colon and rectal surgery, otolaryngology, and pain medicine.

Patricia Ganz, MD (Co-Chair) (Clinical Oncology) Los Angeles, CA
James Hayman, MD (Co-Chair) (Radiation Oncology) Ann Arbor MI
Joseph Bailes, MD (Clinical Oncology) The Woodlands, TX
Nancy Baxter, MD, PhD (Colorectal Surgery) Toronto, Ontario Canada
Joel V. Brill, MD (Gastroenterology) Phoenix, AZ
Steven B. Clauser, PhD (Outcomes Research) Bethesda, MD
Charles Cleeland, PhD (Oncology) Houston, TX
J. Thomas Cross, Jr. MD, MPH (Oncology) Colorado Springs, CO
Chaitanya R. Divgi, MD (Nuclear Medicine) Philadelphia, PA
Stephen B. Edge, MD (Surgical Oncology) Buffalo, NY
Patrick L. Fitzgibbons, MD (Oncology) Fullerton, CA
Myron Goldsmith, MD (Oncology) Huntington Beach, CA
Joel W. Goldwein, MD (Oncology) Merion Station, PA
Alecia Hathaway, MD, MPH (Oncology) Fort Worth, TX
Kevin P. Hubbard, DO (Oncology) Kansas City, MO
Nora Janjan, MD, MPSA (Radiation Oncology) Houston, TX
Maria Kelly, MB, BCh (Radiation Oncology) Earlysville, VA
Wayne Koch, MD (Head and Neck surgery) Columbia, MD
Andre Konski, MD (Radiation Oncology) Philadelphia, PA
Len Lichtenfeld, MD (Oncology) Atlanta, GA

Norman J. Marcus, MD (Anesthesiology and Psychiatry) New York, NY
Catherine Miyamoto, RN, BSN (Oncology) Grand Forks, ND
Michael Neuss, MD (Oncology, Hematology) Cincinnati, OH
David F. Penson, MD, MPH (Urology) Nashville, TN
Louis Potters, MD (Radiation Oncology) New Hyde Park, NY
John M. Rainey, MD (Medical Oncology) Lafayette, LA
Christopher M. Rose, MD (Radiation Therapy) Beverly Hills, El Segundo, CA
Lee Smith, MD (Oncology) Washington, DC
Lawrence A. Solberg, MD, PhD (Oncology) Jacksonville, FL
Paul E. Wallner, MD (Radiation Oncology) Willingboro, NJ
J. Frank Wilson, MD (Radiation Oncology) Milwaukee, WI

2b2.2 Analytic Method *(Describe method of validity testing and rationale; if face validity, describe systematic assessment)*:
All PCPI performance measures are assessed for content validity by a panel of expert work group members during the development process. Additional input on the content validity of draft measures is obtained through a 30-day public comment period and by also soliciting comments from a panel of consumer, purchaser, and patient representatives convened by the PCPI specifically for this purpose. All comments received are reviewed by the expert work group and the measures adjusted as needed. Other external review groups (eg, focus groups) may be convened if there are any remaining concerns related to the content validity of the measures.

The expert panel was used to assess face validity of the measure. This panel consisted of 31 members, with representation from the following specialties: oncology, radiation oncology, surgical oncology, urology, gastroenterology, hematology, pathology, colon and rectal surgery, otolaryngology, and pain medicine.

The aforementioned panel was asked to rate their agreement with the following statement:

The scores obtained from the measure as specified will accurately differentiate quality across providers.

Scale 1-5, where 1=Strongly Disagree; 3=Neither Disagree nor Agree; 5=Strongly Agree

2b2.3 Testing Results *(Statistical results, assessment of adequacy in the context of norms for the test conducted; if face validity, describe results of systematic assessment)*:
The results of the expert panel rating of the validity statement were as follows: N = 18; Mean rating = 4.39.

Percentage in the top two categories (4 and 5): 94.44%

Frequency Distribution of Ratings
1-   0
2-   1
3-   0
4-   8
5-   9

POTENTIAL THREATS TO VALIDITY. (*All potential threats to validity were appropriately tested with adequate results.*)

2b3. Measure Exclusions. (*Exclusions were supported by the clinical evidence in 1c or appropriately tested with results demonstrating the need to specify them.*)

2b3.1 Data/Sample for analysis of exclusions *(Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included)*:
This measure has no exceptions.

2b3.2 Analytic Method (*Describe type of analysis and rationale for examining exclusions, including exclusion related to patient preference*):
This measure has no exceptions.

2b3.3 Results *(Provide statistical results for analysis of exclusions, e.g., frequency, variability, sensitivity analyses):*
This measure has no exceptions.

2b4. Risk Adjustment Strategy. (*For outcome measures, adjustment for differences in case mix (severity) across measured entities was appropriately tested with adequate results.*)

2b4.1 Data/Sample *(Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included)*:
This measure is not risk adjusted.

2b4.2 Analytic Method (*Describe methods and rationale for development and testing of risk model or risk stratification including selection of factors/variables)*:
This measure is not risk adjusted.

2b4.3 Testing Results (*Statistical risk model: Provide quantitative assessment of relative contribution of model risk factors; risk model performance metrics including cross-validation discrimination and calibration statistics, calibration curve and risk decile plot, and assessment of adequacy in the context of norms for risk models. Risk stratification: Provide quantitative assessment of relationship of risk factors to the outcome and differences in outcomes among the strata)*:
Not Applicable

2b4.4 If outcome or resource use measure is not risk adjusted, provide rationale and analyses to justify lack of adjustment: Not Applicable

2b5. Identification of Meaningful Differences in Performance. (*The performance measure scores were appropriately analyzed and discriminated meaningful differences in quality.*)

2b5.1 Data/Sample *(Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included)*:
PCPI Testing Project
- 160 patient records were reviewed for this measure.
- The measurement period (data collected from patients seen) was 1/1/2010 through 12/31/2010.
- Chart abstraction was performed between 8/8/2011 and 11/3/2011.

2b5.2 Analytic Method *(Describe methods and rationale to identify statistically significant and practically/meaningfully differences in performance)*:
PCPI Testing Project
Data analysis performed on the measure included:
Average measure performance rate overall and by site, performance rate range by site and overall standard deviation for the measure.

2b5.3 Results *(Provide measure performance results/scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance)*:
 PCPI Testing Project
Measure rate without exceptions: N= 160 Mean = 96.9% Standard Deviation= 0.1745

The performance rate by site is as follows, where n is the number of performance events by site:

A	0.9330	n=30
B	0.9330	n=30
C	1.0000	n=30
D	1.0000	n=30
E	0.9750	n=40

The performance rate range is .0670. Although this study captured performance on 160 events, the data were not captured at the physician level, restricting reporting of variation in performance to the organization level only. Additionally, we are unable to present

a meaningful calculation of variation in performance across organizations due to the small sample size of sites (n=5) in this study.

2b6. Comparability of Multiple Data Sources/Methods. (*If specified for more than one data source, the various approaches result in comparable scores.*)

2b6.1 Data/Sample (*Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included*):
This measure has not been compared across data sources.

2b6.2 Analytic Method (*Describe methods and rationale for testing comparability of scores produced by the different data sources specified in the measure*):
This measure has not been compared across data sources.

2b6.3 Testing Results (*Provide statistical results, e.g., correlation statistics, comparison of rankings; assessment of adequacy in the context of norms for the test conducted*):
This measure has not been compared across data sources.

2c. Disparities in Care: H☐ M☐ L☐ I ☐ NA☐ (*If applicable, the measure specifications allow identification of disparities.*)

2c.1 If measure is stratified for disparities, provide stratified results (*Scores by stratified categories/cohorts*): We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

2c.2 If disparities have been reported/identified (e.g., in 1b), but measure is not specified to detect disparities, please explain:
The PCPI advocates that performance measure data should, where possible, be stratified by race, ethnicity, and primary language to assess disparities and initiate subsequent quality improvement activities addressing identified disparities, consistent with recent national efforts to standardize the collection of race and ethnicity data. A 2008 NQF report endorsed 45 practices including stratification by the aforementioned variables.(1) A 2009 IOM report "recommends collection of the existing Office of Management and Budget (OMB) race and Hispanic ethnicity categories as well as more fine-grained categories of ethnicity(referred to as granular ethnicity and based on one's ancestry) and language need (a rating of spoken English language proficiency of less than very well and one's preferred language for health-related encounters)."(2)

References:
(1)National Quality Forum Issue Brief (No.10). Closing the Disparities Gap in Healthcare Quality with Performance Measurement and Public Reporting. Washington, DC: NQF, August 2008.

(2)Race, Ethnicity, and Language Data: Standardization for Health Care Quality Improvement. March 2010. AHRQ Publication No. 10-0058-EF. Agency for Healthcare Research and Quality, Rockville, MD. Available at: http://www.ahrq.gov/research/iomracereport. Accessed May 25, 2010.

2.1-2.3 Supplemental Testing Methodology Information:

Steering Committee: Overall, was the criterion, *Scientific Acceptability of Measure Properties*, met?
(*Reliability and Validity must be rated moderate or high*) Yes☐ No☐
Provide rationale based on specific subcriteria:

If the Committee votes No, STOP

3. USABILITY

Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making. (evaluation criteria)

C.1 **Intended Purpose/ Use** *(Check all the purposes and/or uses for which the measure is intended)*: Professional Certification or Recognition Program, Public Reporting, Quality Improvement (Internal to the specific organization), Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

3.1 **Current Use** *(Check all that apply; for any that are checked, provide the specific program information in the following questions)*: Public Reporting, Professional Certification or Recognition Program, Quality Improvement with Benchmarking (external benchmarking to multiple organizations), Quality Improvement (Internal to the specific organization)

3a. Usefulness for Public Reporting: H☐ M☐ L☐ I☐
(*The measure is meaningful, understandable and useful for public reporting.*)

3a.1. **Use in Public Reporting - disclosure of performance results to the public at large** *(If used in a public reporting program, provide name of program(s), locations, Web page URL(s)).* If not publicly reported in a national or community program, state the reason AND plans to achieve public reporting, potential reporting programs or commitments, and timeline, e.g., within 3 years of endorsement: [*For Maintenance – If not publicly reported, describe progress made toward achieving disclosure of performance results to the public at large and expected date for public reporting; provide rationale why continued endorsement should be considered.*]
This measure was used in the CMS Physician Quality Reporting System program in 2010 and 2011 and is currently in use in PQRS 2012. Information on the PQRS program can be found at: https://www.cms.gov/PQRS.

The PCPI believes that the reporting of participation information is a beneficial first step on a trajectory toward the public reporting of performance results, which is appropriate since the measure has been tested and the reliability of the performance data has been validated. Continued NQF endorsement will facilitate our ongoing progress toward this public reporting objective.

3a.2. **Provide a rationale for why the measure performance results are meaningful, understandable, and useful for public reporting**. If usefulness was demonstrated (e.g., focus group, cognitive testing), describe the data, method, and results: The PCPI believes that the reporting of participation information is a beneficial first step on a trajectory toward the public reporting of performance results, which is appropriate since the measure has been tested and the reliability of the performance data has been validated. Continued NQF endorsement will facilitate our ongoing progress toward this public reporting objective.

3.2 **Use for other Accountability Functions (payment, certification, accreditation)**. If used in a public accountability program, provide name of program(s), locations, Web page URL(s): This measure may be used in a Maintenance of Certification program, including the following current initiatives:

QOPI data can be used to meet the ABIM's practice Performance Improvement Module (PIM) requirement for Maintenance of Certification.

PAAROT is ASTRO´s Maintenance of Certification program that is recognized by the American Board of Radiology (ABR) as a Type 2 PQI project in partial fulfillment of the MOC requirements.

3b. **Usefulness for Quality Improvement:** H☐ M☐ L☐ I☐
(*The measure is meaningful, understandable and useful for quality improvement.*)

3b.1. **Use in QI.** If used in quality improvement program, provide name of program(s), locations, Web page URL(s):
[*For Maintenance – If not used for QI, indicate the reasons and describe progress toward using performance results for improvement*].
A slight adaptation of this measure is currently being used in ASCO´s Quality Oncology Practice Initiative (QOPI®) program. QOPI is a physician-led, voluntary, practice-based, quality-improvement program using performance measurement and benchmarking among oncology practices across the United States. QOPI´s goal is to promote excellence in cancer care by helping practices create a culture of self-examination and improvement. The process employed for improving cancer care includes measurement, feedback and improvement tools for hematology-oncology practices.

All PCPI measures are suitable for use in quality improvement initiatives and are made freely available on the PCPI website and through the implementation efforts of medical specialty societies and other PCPI members. The PCPI strongly encourages the use of its measures in QI initiatives and seeks to provide information on such initiatives to PCPI members.

3b.2. Provide rationale for why the measure performance results are meaningful, understandable, and useful for quality improvement. If usefulness was demonstrated *(e.g., QI initiative),* describe the data, method and results:

The PCPI believes that the use of PCPI measures in quality improvement initiatives is a beneficial way to gather scientific data with which to improve physician performance. This is appropriate since the measure has been tested and the reliability of the performance data has been validated. NQF endorsement will facilitate our ongoing progress toward this quality improvement objective.

Overall, to what extent was the criterion, *Usability*, met? H☐ M☐ L☐ I☐
Provide rationale based on specific subcriteria:

4. FEASIBILITY

Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. **(evaluation criteria)**

4a. Data Generated as a Byproduct of Care Processes: H☐ M☐ L☐ I☐

4a.1-2 How are the data elements needed to compute measure scores generated? *(Check all that apply).*
Data used in the measure are:
generated by and used by healthcare personnel during the provision of care, e.g., blood pressure, lab value, medical condition

4b. Electronic Sources: H☐ M☐ L☐ I☐

4b.1 Are the data elements needed for the measure as specified available electronically *(Elements that are needed to compute measure scores are in defined, computer-readable fields)*: ALL data elements in electronic health records (EHRs)

4b.2 If ALL data elements are not from electronic sources, specify a credible, near-term path to electronic capture, OR provide a rationale for using other than electronic sources:

4c. Susceptibility to Inaccuracies, Errors, or Unintended Consequences: H☐ M☐ L☐ I☐

4c.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measurement identified during testing and/or operational use and strategies to prevent, minimize, or detect. If audited, provide results:
We are not aware of any unintended consequences related to this measurement.

4d. Data Collection Strategy/Implementation: H☐ M☐ L☐ I☐

A.2 Please check if either of the following apply *(regarding proprietary measures)*:
4d.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data, missing data, timing and frequency of data collection, sampling, patient confidentiality, time and cost of data collection, other feasibility/implementation issues *(e.g., fees for use of proprietary measures)*:
This measure was found to be reliable and feasible for implementation.

Overall, to what extent was the criterion, *Feasibility*, met? H☐ M☐ L☐ I☐
Provide rationale based on specific subcriteria:

OVERALL SUITABILITY FOR ENDORSEMENT

Does the measure meet all the NQF criteria for endorsement? Yes☐ No☐
Rationale:

If the Committee votes No, STOP.
If the Committee votes Yes, the final recommendation is contingent on comparison to related and competing measures.

5. COMPARISON TO RELATED AND COMPETING MEASURES

If a measure meets the above criteria and there are endorsed or new related measures (either the same measure focus or the same target population) or competing measures (both the same measure focus and the same target population), the measures are

compared to address harmonization and/or selection of the best measure before a final recommendation is made.

5.1 If there are related measures *(either same measure focus or target population)* or competing measures *(both the same measure focus and same target population)*, list the NQF # and title of all related and/or competing measures:
0455 : Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection

5a. Harmonization

5a.1 If this measure has EITHER the same measure focus OR the same target population as NQF-endorsed measure(s): Are the measure specifications completely harmonized? No

5a.2 If the measure specifications are not completely harmonized, identify the differences, rationale, and impact on interpretability and data collection burden:
Although the numerator language is not precisely harmonized, both measure numerators are conceptually similar. Our measure requires a documentation of AJCC stage which utilizes the TNM scoring system that is required by measure 0455.

5b. Competing Measure(s)

5b.1 If this measure has both the same measure focus and the same target population as NQF-endorsed measure(s): Describe why this measure is superior to competing measures *(e.g., a more valid or efficient way to measure quality)*; OR provide a rationale for the additive value of endorsing an additional measure. *(Provide analyses when possible)*:

CONTACT INFORMATION

Co.1 Measure Steward (Intellectual Property Owner): American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI), 515 N State Street, Chicago, Illinois, 60654

Co.2 Point of Contact: Mark S., Antman, DDS, MBA, Director, Measure Development Operations Performance Improvement, mark.antman@ama-assn.org, 312-464-5056-

Co.3 Measure Developer if different from Measure Steward: AMA-PCPI and American Society of Clinical Oncology, 515 N. State St., Chicago, Illinois, 60654

Co.4 Point of Contact: Samantha, Tierney, MPH, samantha.tierney@ama-assn.org, 312-464-5524-

Co.5 Submitter: Mark S., Antman, DDS, MBA, Director, Measure Development Operations Performance Improvement, mark.antman@ama-assn.org, 312-464-5056-, American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)

Co.6 Additional organizations that sponsored/participated in measure development:
This measure is jointly copyrighted by the AMA-PCPI and American Society of Clinical Oncology. The measure set was also developed in collaboration with the American Society for Radiation Oncology.

Co.7 Public Contact: Mark S., Antman, DDS, MBA, Director, Measure Development Operations Performance Improvement, mark.antman@ama-assn.org, 312-464-5056-, American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)

ADDITIONAL INFORMATION

Workgroup/Expert Panel involved in measure development
Ad.1 Provide a list of sponsoring organizations and workgroup/panel members' names and organizations. Describe the members' role in measure development.
Patricia Ganz, MD (Co-Chair)
James Hayman, MD (Co-Chair)
Joseph Bailes, MD
Nancy Baxter, MD, PhD

PCPI measures are developed through cross-specialty, multi-disciplinary work groups. All medical specialties and other health care professional disciplines participating in patient care for the clinical condition or topic under study are invited to participate as equal contributors to the measure development process. In addition, the PCPI strives to include on its work groups individuals representing the perspectives of patients, consumers, private health plans, and employers. This broad-based approach to measure development ensures buy-in on the measures from all stakeholders and minimizes bias toward any individual specialty or stakeholder group. All work groups have at least two co-chairs who have relevant clinical and/or measure development expertise and who are responsible for ensuring that consensus is achieved and that all perspectives are voiced.

Ad.2 If adapted, provide title of original measure, NQF # if endorsed, and measure steward. Briefly describe the reasons for adapting the original measure and any work with the original measure steward:

Measure Developer/Steward Updates and Ongoing Maintenance
Ad.3 Year the measure was first released: 2007
Ad.4 Month and Year of most recent revision: 12, 2011
Ad.5 What is your frequency for review/update of this measure? Coding/Specifications updates occur annually. See additional information below.
Ad.6 When is the next scheduled review/update for this measure? 2012

Ad.7 Copyright statement: Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement® (the Consortium), are intended to facilitate quality improvement activities by physicians.
These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.
Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered

Ad.8 Disclaimers: See copyright statement above.

Ad.9 Additional Information/Comments: The PCPI has a formal measurement review process that stipulates regular (usually on a three-year cycle, when feasible) review of the measures. The process can also be activated if there is a major change in scientific evidence, results from testing or other issues are noted that materially affect the integrity of the measure.

Date of Submission (*MM/DD/YY*): 10/03/2011

PCPI ONCOLOGY: CANCER STAGE DOCUMENTED (NQF# 0386)

Measure #0386: Oncology: Cancer Stage Documented

QDM* Standard Category	QDM* Data Type	Standard Terminology	Constraints	Value Set Name	Value of Data Element	Data Source	Comments/Rationale
Measure Timing	N/A	N/A	TBD by measure implementer	Measurement Start Date			
Measure Timing	N/A	N/A	TBD by measure implementer	Measurement End Date			
Individual Characteristic	Patient Characteristic	Gender HL7 Value Set (2.16.840.1.113883.1.11.1)	during measurement period	Gender		• Electronic Health Record (EHR)	This data element is collected for the purpose of stratifying results in an effort to highlight disparities.
Individual Characteristic	Patient Characteristic	Race CDC Value Set (2.16.840.1.114222.4.11.836)	during measurement period	Race		• Electronic Health Record (EHR)	This data element is collected for the purpose of stratifying results in an effort to highlight disparities.
Individual Characteristic	Patient Characteristic	Ethnicity CDC Value Set (2.16.840.1.114222.4.11.837)	during measurement period	Ethnicity		• Electronic Health Record (EHR)	This data element is collected for the purpose of stratifying results in an effort to highlight disparities.
Individual Characteristic	Patient Characteristic	Payer Source of Payment Typology Value Set (2.16.840.1.113883.3.221.5)	during measurement period	Payer		• Electronic Health Record (EHR)	This data element is collected for the purpose of stratifying results in an effort to highlight disparities.
Individual Characteristic	Patient Characteristic	Primary spoken language (2.16.840.1.114222.4.11.831)	during measurement period	Preferred Language		• Electronic Health Record (EHR)	This data element is collected for the purpose of stratifying results in an effort to highlight disparities.
Individual Characteristic	Patient Characteristic	LOINC (2.16.840.1.113883.3.560.100.4)	starts before the start of measurement period	Birth date		• Electronic Health Record (EHR)	
Individual Characteristic	Patient Characteristic	Calculated	starts before the start of measurement period	Age	All ages	• Electronic Health Record (EHR)	For this measure, there are no restrictions on age for denominator inclusion. Collected for possible stratification of data.
Encounter	Encounter, Performed	CPT (TBD)	during measurement period	Ambulatory Visit		• Electronic Health Record (EHR)	
Encounter	Encounter, Performed	SNOMED-CT (2.16.840.1.113883.3.526.03.1012)	during measurement period	Patient Provider Interaction		• Electronic Health Record (EHR)	
Diagnosis	Diagnosis, Active	ICD-9-CM, ICD-10-CM, SNOMED-CT (TBD)	during measurement period	Breast Cancer		• Electronic Health Record (EHR)	
Diagnosis	Diagnosis, Active	ICD-9-CM, ICD-10-CM, SNOMED-CT (TBD)	during measurement period	Colon Cancer		• Electronic Health Record (EHR)	
Diagnosis	Diagnosis, Active	ICD-9-CM, ICD-10-CM, SNOMED-CT (TBD)	during measurement period	Rectal Cancer		• Electronic Health Record (EHR)	
Laboratory Test	Laboratory Test, Result	LOINC (TBD)	during measurement period	Metastatic Cancer		• Electronic Health Record (EHR)	
Attribute	Attribute: Result	(TBD)	during measurement period	Baseline AJCC Cancer Stage Present		• Electronic Health Record (EHR)	

*The Quality Data Model (QDM), Version 2.1, was developed by National Quality Forum (NQF).

CPT ® Copyright 2004-2011 American Medical Association. All Rights Reserved.

Basic Measure Calculation:

$$\frac{(N)}{(D) - (E)} = \%$$

The PCPI strongly recommends that exception rates also be computed and reported alongside performance rates as follows:

Exception Calculation:

$$\frac{(E)}{(D)} = \%$$

Exception Types:
E= E1 (Medical Exceptions) + E2 (Patient Exceptions) + E3 (System Exceptions)
For patients who have more than one valid exception, only one exception should be be counted when calculating the exception rate

Initial Patient Population (IPP)	Denominator (D)	Numerator (N)	Denominator Exceptions (E)
Definition: The initial patient population identifies the general group of patients that the performance measureis designed to address; usually focused on a specific clinical condition (e.g., coronary artery disease, asthma). For example, a patient aged 18 years and older with a diagnosis of CADwho has at least 2 Visits during the measurement period.	**Definition:** The denominator defines the specific group of patients for inclusion in a specific performance measure based on specific criteria (e.g., patient's age, diagnosis, prior MI). In some cases, the denominator may be I dentical to the initial patient population.	**Definition:** The numerator defines the group of patients in the denominator for whom a process or outcome of care occurs (e.g., flu vaccine received).	**Definition:** Denominator exceptions are the valid reasons why patients who are included in the denominator population did not receive a process or outcome of care (described in the numerator). Patients may have Denominator Exceptions for medical reasons (e.g., patient has an egg allergy so they did not receive flu vaccine); patient reasons (e.g., patient declined flu vaccine); or system reasons (e.g., patient did not receive flu Vaccine due to vaccine shortage). These cases are removed from the denominator population for the performance calculation, however the number of patients with valid exceptions should be calculated and reported. This group of patients constitutes the Denominator Exception reporting population – patients for whom the numerator was not achieved and a there is a valid Denominator Exception.
Find the patients who meet the Initial Patient Population criteria (IPP)	Find the patients who qualify for the denominator (D): ○ From the patients within the Patient Population criteria (IPP) select those people who meet Denominator selection criteria. (In some cases the IPP and D are identical).	Find the patients who qualify for the Numerator (N): ○ From the patients within the Denominator (D) criteria, select those people who meet Numerator selection criteria. ○ Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator	From the patients who did not meet the Numerator criteria, determine if the patient meets any criteria for the Denominator Exception (E1 + E2+E3). If they meet any criteria, they should be removed from the Denominator for performance calculation. As a point of reference, these cases are removed from the denominator population for the performance calculation, however the number of patients with valid exceptions should be calculated and reported.

Version 1.2

(C) Copyright 2010 American Medical Association. All Rights Reserved.